Glenmark Obtains US FDA Approval for Nasal Spray

Pharmaceutical major Glenmark Pharmaceuticals Limited said its 100% Swiss subsidiary on Friday Glenmark Specialty SA received the US Food and Drug Administrationit is (FDA) approval of fixed-dose prescription nasal spray drug for seasonal allergic rhinitis Ryaltris.

According to Glenmark, the drug is intended for rhinitis in adults and pediatric patients 12 years and older in the United States.

“The FDA approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to deliver innovative treatment options in our key therapeutic areas. said the commercial director Robert Crockart.

Ryaltris will be marketed and distributed in America by Hikma Specialty USA, Inc., under its exclusive license agreement with Glenmark Specialty SA

Glenmark has entered into commercial agreements with several partners around the world, including Menarini for the commercialization of Ryaltris in certain European markets, and with Bausch Health in Canada (where it is under review by Health Canada), the company said. .

Three out of four COVID-19 deaths in Delhi are unvaccinated patients

Tesla to start accepting dogecoins for merchandise, Musk tweets


About Author

Comments are closed.